



## Hydroxychloroquine and QT Prolongation in Older Patients with Rheumatic Diseases: Who is afraid of the Boogeyman? We are not!

Alberto Castagna<sup>1</sup> , Giovanni Ruotolo<sup>2</sup>, **Ciro Manzo**<sup>3</sup> 

<sup>1</sup>Azienda Sanitaria Provinciale Catanzaro, Geriatric Medicine department - Fragility Outpatient Clinic, Casa della Salute Chiaravalle Centrale, Catanzaro, Italy, <sup>2</sup>Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro, Geriatric Unit, General Hospital, Catanzaro, Italy, <sup>3</sup>Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine department – Geronthorheumatological Outpatient Clinic, poliambulatorio “Mariano Lauro”, Sant’Agnello, Naples, Italy

*Mediterr J Rheumatol* 2020;31(4):433-5

<https://doi.org/10.31138/mjr.31.4.433>

Article Submitted: 5 Jul 2020; Revised Form: 7 Sep 2020; Article Accepted: 30 Sep 2020; Available Online: 22 Dec 2020

Dear Editors,

The role of hydroxychloroquine (HCQ) sulphate as a therapeutic option in coronavirus disease 2019 (COVID-19) patients aroused great interest and hope.<sup>1-3</sup>

In these months, the possibility that HCQ could cause adverse cardiac events when used in association with azithromycin has been brought to the attention of the scientific, and not only, community. In particular, Chorin et al. in patients treated with HCQ and azithromycin, observed prolongation of the corrected QT interval (QTc) from a baseline average of  $435 \pm 24$  ms (mean  $\pm$  sd) to a maximal average value of  $463 \pm 32$  ms ( $P < 0.001$  (one-sample *t*-test)) which occurred on day  $3.6 \pm 1.6$  of therapy.<sup>4</sup> Mercurio et al. observed that patients who received HCQ for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTc.<sup>5</sup>

As known, QT is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation. The

QTc estimates the QT interval at a standard heart rate of 60 bpm. This allows comparison of QT values over time at different heart rates and improves detection of patients at increased risk of arrhythmias. The normal QTc interval in adults is

0.36 to 0.47 seconds (360-470 milliseconds) in males and 0.36 to 0.48 seconds (360-480 ms) in females. In a small percentage of patients, QT interval prolongation (defined as  $\geq 470$  ms in males and  $\geq 480$  ms in females), can trigger torsades de pointes (TdP). This risk is not a linear function of QTc values. TdP is, by definition, a form of polymorphic ventricular tachycardia with a heart rate greater than 100 beats per minute with characteristic twisting around the isoelectric baseline every 5-20 beats. TdP is associate with a high risk of sudden death.<sup>6</sup>

Among the known medications reported to cause QT interval prolongation, HCQ is not commonly implicated. In 2017, during the Malaria policy advisory committee meeting organised by the World Health Organization (WHO), no case of arrhythmic death was reported.<sup>7</sup> In 2018, a systematic review article reported that the risk of cardiac adverse events (conduction disorders, among these) was not quantifiable because of the lack of randomised controlled trials and observational studies investigating this association.<sup>8</sup> To date, only case reports and case series of very small size are present in the literature.

The proposed mechanism by which HCQ causes QT interval prolongation is not well understood. Capel et al. observed in guinea pig sinoatrial node myocytes findings consistent with inhibitory effects of HCQ on the hyperpolarization activated current ion channels (also known as “funny current” channels), along with delayed rectifier potassium currents and L-type calcium ion currents. These inhibitory effects on the pacemaker cells were shown to cause delayed rates in depolarization leading to decreased heart rates.<sup>9</sup>

It is a common knowledge that QTc increases with age, and recent data suggest that frailty-related phenotypes

### Corresponding Author:

Ciro Manzo  
Poliambulatorio “Mariano Lauro”  
Viale dei Pini 1  
80065 Sant’Agnello, Naples, Italy  
Tel.: +39 081 533 1465  
Fax: +39 081 533 1449  
Email : manzoreumatologo@libero.it

**Table 1.** Drugs associated with a known risk of QT prolongation.

Drug Class	Known risk of QT prolongation
Anaesthetic, general	Propofol, Sevoflurane
Antiarrhythmic	Amiodarone, Disopyramide Phosphate, Flecainide, Ibutilide, Procainamide, Quinidine, Sotalol
Antidepressant	Citalopram, Escitalopram
Anticancer	Arsenic Trioxide, Eribulin, Vandetanib
Antiemetic	Ondansetron, Droperidol
Antifungal	Fluconazole, Pentamidine
Antimalaric	Chloroquine, Halofantrine
Antipsychotic	Chlorpromazine, Haloperidol, Pimozide, Thioridazine
Antibiotic	Azithromycin, Clarithromycin, Erythromycin, Ciprofloxacin, Levofloxacin, Moxifloxacin
Cholinesterase inhibitor	Donepezil
Illicit Drug	Cocaine
Opiates	Methadone
Phosphodiesterase 3 Inhibitor	Anagrelide, Cilostazol

are associated with QTc prolongation. For instance, inactivity and light-intensity physical activity were associated with QTc prolongation in older adults.<sup>10</sup>

With the progressive lengthening of life, the possibility that inflammatory rheumatic diseases are diagnosed in the elderly is increasing. In older patients, polypharmacy is frequent, and age-induced changes in pharmacokinetics may create completely different scenarios compared to adult or young populations.<sup>1</sup>

In clinical practice, the risk for QTc interval prolongation must always be assessed in older patients affected by inflammatory rheumatic diseases, before starting HCQ therapy. Particular caution is advised when combining QT-prolonging medications (**Table 1**).

In 2013, Tisdale et al. proposed an algorithm to quantify this risk.<sup>11</sup> Maximum score is 21, and total score classified patients in high (equal or higher than 11 points), moderate (7-10 points) and low risk (less than 6 points) (**Table 2**). In our clinical practice, routine use of the Tisdale scale proved very useful to identify and minimise this specific risk.

In line with Tisdale's algorithm, an electrocardiographic (ECG) control is fundamental as well as it is prudent to correct electrolyte disorders (mainly hypokalaemia and hypomagnesaemia), and, where possible, avoid or minimize use of other drugs known to prolong the QT interval in relation to comorbidity and poly-pharmaco-therapy. History of long QT syndrome, or baseline QTc prolongation, or Tisdale risk score > 11 should suggest other different drugs or, alternatively, a tight and short-time ECG control.

**Table 2.** Calculation of risk score for QTc interval prolongation (modified by Tisdale et al., 2013).

Risk Factor	Point
Age ≥ 68 years	1
Female Sex	1
Loop Diuretic	1
Serum Potassium ≤ 3,5 mEq/L	2
Admission QTc ≥ 450 ms	2
Acute Myocardial Infarction	2
≥ 2 QTc Prolonging Drugs*	3
Sepsis	3
Heart Failure	3
One QTc Prolonging Drugs*	3
<b>Maximum Risk Score</b>	<b>21</b>

\*Three points for taking one QTc interval-prolonging drug; 3 additional points for taking ≥ 2 QTc interval-prolonging drugs (for a total of 6 points).

Moreover, as already highlighted, randomised controlled trials and observational studies investigating the association between HCQ and QTc values are still lacking. Routine use of the Tisdale scale could provide useful information regard this potential risk.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## REFERENCES

1. Manzo C. The role of hydroxychloroquine sulphate in the geriatric patient with coronavirus disease 2019 (COVID-19). What is useful to know for the geriatrician? *Geriatric Care* 2020;6:25-8.
2. Coronavirus Disease (COVID-19) events as they happen. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-theyhappen>. Accessed July 4, 2020.
3. Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI. When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? *Mediterr J Rheumatol* 2020;31:94-7.
4. Chorin E, Dai M, Shulman E, Wadhvani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. *Nat Med* 2020 Jun;26(6):808-09.
5. Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020 Sep 1;5(9):1036-41.
6. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. *Medical Clinics of North America*. 2001;85:321–341. doi: 10.1016/s0025-7125(05)70318-7.
7. World Health Organization. Malaria policy advisory committee meeting: the cardiotoxicity of antimalarials; 22 March, 2017, pp. 6-7. Available from: <http://www.who.int>
8. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. *Drug Saf* 2018;41:919-31.
9. Capel R, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current *if*: novel electrophysiological insights and therapeutic potential. *Heart Rhythm* 2015;12:2186-94.
10. Michishita R, Fukae C, Mihara R, Ikenaga M, Morimura K, Takeda N, et al. Association between the physical activity and heart rate corrected-QT interval in older adults. *Geriatr Gerontol Int* 2015;15:895-901.
11. Tisdale JE, Jayes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. *Circ Cardiovasc Qual Outcomes* 2013;6:479-487.

# CREATING INNOVATION

We are the innovative biotech that helps halt HIV, eradicate Hep C and develop new cell therapies (CAR-Ts).

Today, at Gilead we are researching innovative therapies for people with inflammatory diseases.

You have accomplished a lot for your patients with Rheumatoid Arthritis and together we will achieve even more.

To find out more about Gilead's vision, please visit

[www.RAneedsinnovation.gr](http://www.RAneedsinnovation.gr)

GR-INF-2020-03-0001 (v.2)



**GILEAD**

Creating Possible